Pseudomonas-dominant microbiome elicits sustained IL-1β upregulation in alveolar macrophages from lung transplant

Noel Britton1, Andres Villabona-Rueda1, Samantha A Whiteside2

  • 1Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, Maryland.

Abstract

Insights

Pseudomonas aeruginosa (PsA) and PsA-dominant lung microbiota trigger sustained IL-1β release from lung transplant recipient alveolar macrophages. Targeting the inflammasome effectively reduces these PsA-induced responses, offering potential therapeutic strategies for lung transplant recipients.

Area of Science:

  • Immunology
  • Microbiology
  • Transplantation Science

Background:

  • Pseudomonas aeruginosa (PsA) isolation correlates with increased lung allograft inflammation and injury in lung transplant recipients (LTR).
  • The impact of PsA on macrophage responses in LTR is not fully understood.
  • This study investigates human alveolar macrophage (AMΦ) responses to PsA and Pseudomonas-dominant microbiomes in LTR.

Purpose of the Study:

  • To analyze human alveolar macrophage (AMΦ) responses to Pseudomonas aeruginosa (PsA).
  • To investigate the effect of PsA-dominant lung microbiota on AMΦ.
  • To explore the role of the inflammasome in PsA-macrophage interactions in lung transplant recipients (LTR).

Main Methods:

  • THP-1 derived macrophages (THP-1MΦ) and LTR AMΦ were stimulated with bacteria and LTR BAL-derived microbiome.
  • Macrophage responses, including intracellular cytokine production (TNF-α, IL-6, IL-8, IL-1β, IL-10, IL-1RA, TGF-β), were measured using high-dimensional flow cytometry.
  • Pharmacological inflammasome inhibitors were used to assess the inflammasome's role in PsA-macrophage interactions.

Main Results:

  • PsA stimulation led to increased pro-inflammatory cytokine production (TNF-α, IL-6, IL-8, IL-1β) in both THP-1MΦ and LTR AMΦ, with IL-1β predominating.
  • Sustained IL-1β production was observed for up to 96 hours in THP-1MΦ and 48 hours in LTR AMΦ post-PsA stimulation.
  • Inflammasome inhibition (BAY11-7082) abrogated IL-1β production, and PsA-dominant microbiota induced similar IL-1β responses, which were reduced by antibiotics.

Conclusions:

  • PsA and PsA-dominant lung microbiota induce sustained IL-1β production in LTR AMΦ.
  • Targeting the inflammasome effectively reduces PsA-induced IL-1β responses in macrophages.
  • These findings highlight the potential therapeutic value of inflammasome inhibitors for lung transplant recipients.